Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.46 |
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993390 | 0.98 | ESR2 (0.47) | HAO1ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL14538178 | 0.94 | NOTUM (0.44) | HAO1ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL13368345 | 0.93 | ESR2 (0.52) | HAO1ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL21753177 | 0.89 | LTA4H (0.52) | HAO1ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL742590 | 0.89 | ESR2 (0.52) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL22291713 | 0.85 | HRH3 (0.61) | CYP3A4CYP2C9NAAAASAH1HRH3 | |
| SCHEMBL11676578 | 0.83 | CA2 (0.45) | HAO1ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL4452070 | 0.82 | LTA4H (0.44) | HAO1ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL10102342 | 0.81 | ALDH1A1 (0.36) | HAO1ESR2ESR1CYP3A4CYP2C9 | |
| Hydrogen Peroxide SCHEMBL11391495 | 0.81 | HAO1 (0.55) | HAO1ESR2HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638586-A | Trifluoromethyl cyclohexyl benzyl ether substituted nitrogenous organic acid derivative, preparation method and application thereof | 中国医学科学院药物研究所 | 2025-03-18 | — | — | CN | claimed |
| CN-111315828-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-09-29 | — | — | CN | disclosed |
| CN-112154167-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-08-22 | — | — | CN | disclosed |
| CN-115160098-B | Oxygen-containing compound deoxidization methylation method | 中国科学院兰州化学物理研究所 | 2023-06-06 | — | — | CN | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-115160098-A | Oxygen-containing compound deoxidation and methylation method | 中国科学院兰州化学物理研究所 | 2022-10-11 | — | — | CN | disclosed |
| CN-114539129-A | Allylamine bifunctional compound and application thereof | 上海中医药大学附属龙华医院 | 2022-05-27 | — | — | CN | disclosed |
| US-10954258-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954258-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112154167-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-12-29 | — | — | CN | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| EP-0523697-B1 | Color-developing compositions and their use | MITSUI TOATSU CHEMICALS (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0268878-B1 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5447901-A | Color-developing sheet: base material coated with composition of /a/ multivalent metal-modified salicylic acid resin formed from salicylic acid, a benzyl compound and optional styrene and /b/ analogous resin free of salicylic acid | MITSUI TOATSU CHEMICAL, INC. (JP) | 1995-09-05 | — | — | US | disclosed |
| US-5376615-A | Pressure sensitive elements containing a salicylic acid resin and a phenolic resin | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0523697-A1 | Color-developing compositions and their use | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-20 | — | — | EP | disclosed |
| US-5023366-A | Reacted with a benzyl halide, alcohol or ether; for pressure sensitive elements | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-06-11 | — | — | US | disclosed |
| EP-0268878-A2 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-06-01 | — | — | EP | disclosed |
| US-4721779-A | ELECTROOPTICAL APPARATUS | BASF AKTIENGESELLSCHAFT (DE) | 1988-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | HAO1 2108/4885ESR2 727/4885ESR1 2427/4885 |
| US-10954258-B2 | STAT3 dimerization inhibitors | STAT3, JAK2, STAT1 | HAO1 4476/4885ESR2 709/4885ESR1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.